1. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer
- Author
-
Joseph Celestino, Gordon B. Mills, Li Zhao, Sanghoon Lee, Agda Karina Eterovic, David Cordover, Jianhua Zhang, Nicholas W. Bateman, Tri V. Nguyen, Christine Rojas, Robert L. Coleman, Randy A. Chu, Xingzhi Song, Kelly A. Conrads, Ming Zhou, Coralie Viollet, Jerez Te, Katlin Wilson, Richard A. Hajek, Clifton L. Dalgard, Amir A. Jazaeri, Gloria L. Fawcett, Jeremy Loffredo, Margaret B. Morgan, Olivia D. Lara, Anil K. Sood, Anthony R. Soltis, Karen H. Lu, Nicole D. Fleming, Xizeng Mao, Hui Yao, Shannon N. Westin, Jared K. Burks, P. Andrew Futreal, Brian L. Hood, Andrew K. Dunn, Kristin Roman, Matthew D. Wilkerson, Keith A. Baggerly, Yovanni Casablanca, R.L. Dood, Jinsong Liu, Thomas P. Conrads, Kelly M. Rangel, George L. Maxwell, and Nirad Banskota
- Subjects
Adult ,0301 basic medicine ,Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,Immune monitoring ,Article ,General Biochemistry, Genetics and Molecular Biology ,Transcriptome ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Internal medicine ,medicine ,Serous ovarian cancer ,Humans ,Metabolomics ,Ovarian Neoplasms ,Chemotherapy ,business.industry ,Gene Expression Profiling ,Genomics ,Middle Aged ,Omics ,medicine.disease ,Cystadenocarcinoma, Serous ,Molecular analysis ,030104 developmental biology ,Female ,Ovarian cancer ,business ,030217 neurology & neurosurgery - Abstract
SUMMARY The diversity and heterogeneity within high-grade serous ovarian cancer (HGSC), which is the most lethal gynecologic malignancy, is not well understood. Here, we perform comprehensive multi-platform omics analyses, including integrated analysis, and immune monitoring on primary and metastatic sites from highly clinically annotated HGSC samples based on a laparoscopic triage algorithm from patients who underwent complete gross resection (R0) or received neoadjuvant chemotherapy (NACT) with excellent or poor response. We identify significant distinct molecular abnormalities and cellular changes and immune cell repertoire alterations between the groups, including a higher rate of NF1 copy number loss, and reduced chromothripsis-like patterns, higher levels of strong-binding neoantigens, and a higher number of infiltrated T cells in the R0 versus the NACT groups., Graphical Abstract, In Brief High-grade serous ovarian cancer (HGSC) patients with no gross residual disease (R0) after primary surgery have the greatest improvement in clinical outcomes. A deep understanding of molecular and cellular heterogeneity of HGSC is lacking. Findings by Lee et al. highlight major molecular and cellular differences between clinically defined subgroups of HGSC.
- Published
- 2020
- Full Text
- View/download PDF